Merlinn: The decision layer for pharma data.
Merlinn, offers the clearest public signal of true prescribing behaviour in England. By embedding NHS England Prescription Data (EPD) into Merlinn, this public dataset is transformed into a strategic advantage for pharmaceutical manufacturing and distribution efficiency.
Merlinn is a easy-to-use analytics and reporting platform designed for exploring NHS prescribing data with the latest technology. It allows each organisation to work only with the molecules and data segments that matter to them.
With no need for infrastructure, maintenance, technical teams or operational overhead, companies can access all relevant prescribing information on the same day through a simple subscription.
Merlinn also supports detailed pricing and behavioural analysis to help teams understand prescribing dynamics clearly. Its capabilities are designed for a wide range of roles, enabling BD, manufacturing, commercial excellence, sales and other teams to work confidently with transparent, structured insight.
Compared to existing solutions, Merlinn introduces a distinct decision-support layer for leadership by focusing on system behaviour rather than raw metrics.
The following five most critical core functionalities explain how Merlinn supports senior decision-makers:
1. Behavioural Interpretation of Prescribing Data
Merlinn moves beyond descriptive reporting by interpreting how the prescribing system behaves over time.
By analysing Direction, Persistency, Consistency and Volatility, Merlinn converts complex NHS data into stable Behavioural States that leaders can reason with, rather than react to.
2. Early Awareness of System Shifts
Merlinn identifies behavioural change at molecule and pathway level before it becomes obvious in downstream indicators.
This provides leadership with earlier awareness of system evolution, supporting timely discussion and scenario consideration.
3. Separation of Noise from Structural Change
Short-term fluctuations often obscure long-term movement.
Merlinn filters volatility to distinguish temporary noise from persistent structural momentum, helping leaders focus on changes that genuinely matter.
4. A Shared Interpretation Layer Across Functions
Merlinn provides a single, neutral view of system behaviour, enabling leadership, commercial, medical and access teams to align around the same interpretation of the environment — without prescribing actions or outcomes.
5. System-Level Perspective Across Conditions and Geographies
Merlinn analyses prescribing behaviour at condition level (e.g. ADHD) and molecule level, across national (England), ICB, and GP Surgery geographies.
By viewing prescribing as a connected system rather than isolated components, Merlinn supports leadership understanding of treatment-system evolution, regional divergence, and structural rebalancing over time.
Merlinn Subscription Options
Trial Subscription
-
Data Available at Chemical Level
-
Min 5 Chemicals
-
Customers may Purchase additional bundles of 5 Chemicals
Green Subscription
-
Data Available at Chapter level (data of 1 Chapter include arround 60 -120 chemicals)
-
Min 1 Chapter
-
Includes Region, ICB, PCO, City and Surgery-level insights.
-
2 Users Included
-
+SDS Module (Strategic Decision Scenarios)
Yellow Subscription
-
Data Available at Chemical Level
-
Min 5 Chemicals
-
Includes Region, ICB, PCO, City and Surgery-level insights.
-
Customers may Purchase additional bundles of Chemicals
-
1 User Included
-
+SDS Module (Strategic Decision Scenarios)
Blue Subscription
-
Full market access across all Chapters. (21 Chapter, 1.650 Chemical )
-
Includes Region, ICB, PCO, City and Surgery-level insights.
-
2 Users Included
-
+SDS Module (Strategic Decision Scenarios)
Merlinn Strategic Decision Scenarios (SDS) Module
Merlinn provides a structured way to simulate, evaluate and refine ideas using transparent NHS prescribing data.
Beyond Business Development, the module supports manufacturing, commercial excellence and sales teams by enabling Manufacturing and Sales and distribution scenarios.
Expanded portfolio scenarios reveal molecules where strengthened competition may improve NHS access, affordability and overall system efficiency.
Why Merlinn SDS?
Strategic decisions are not about reacting faster. They are about understanding the system before acting.
Merlinn SDS is designed for senior leaders who need clarity before commitments are made.
It transforms complex NHS prescribing data into a structured decision context, supporting thoughtful and responsible strategy.
Unlike operational analytics tools, SDS focuses on interpretation, alignment, and scenario-based exploration.
Why companies choose SDS
Make decisions with context, not assumptions
SDS helps leadership understand how the system is behaving, reducing reliance on intuition or fragmented views.
Test ideas safely, before acting
SDS provides a secure environment to explore strategic scenarios and evaluate potential outcomes without market risk.
Move from reaction to preparation
By revealing emerging system shifts early, SDS enables companies to prepare rather than respond too late.
Align leadership around one view
SDS creates a shared interpretation layer, ensuring decisions are made from a common understanding of the environment.
Support responsible, system-aligned strategy
SDS does not recommend actions or optimise outcomes. It supports ethical, governance-safe decision-making aligned with healthcare realities.
Merlin SDS Subscription Options
Blue Subscription + SDS Module
-
Full market access across all Chapters. (21 Chapter, 1.650 Chemical )
-
Includes Region and City-level insights.
-
SDS Modules
-
2 users included
Standalone SDS Suite
-
Available as a standalone product or as an add-on to any panel.
-
Specially Developed Molecule Segmentation.
-
Pricing and revenue impact scenarios.
-
Manufacturing optimization and supply chain risk simulations.
-
1 user included
Green Subscription + SDS Module
-
Access at Chapter level (includes data of 1 Chapter).
-
Includes Region and City-level insights.
-
Specially Developed Molecule Segmentation.
-
SDS Module (Chapter molecules)
-
2 users included
Amber Panel
-
Everything to decide to come to the UK
-
Molecule Stratification
-
Grow your business scenario
-
Molecule Sales Report by Geo
-
Reach to Consultancy Supplier for Regulations, Legal and Business